Table 1.
Patients’ clinical characteristics
| Patient No. | Sex | Age (years) | Diagnosis | Status at enrollment | Cycles of CART therapy | Conditioning regimens nab-P (mg/m2), CTX(mg/kg) | CAR-positive T cells in each cycle (×106/kg) | Best response | Progress free survival (months) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | 62 | pCCA | Relapsed/Metastatic | 1 | nab-P 194.8. CTX 29.4 | 3.8 | PR | 4.5 |
| 2 | Male | 61 | iCCA | Relapsed/Metastatic | 1 | nab-P 171.4. CTX 11.9 | 2.9 | PD | |
| 3 | Male | 59 | iCCA | Relapsed/Metastatic | 1 | nab-P 225.7. CTX 8.0 | 2.9 | PD | |
| 4 | Female | 53 | pCCA | Relapsed/Metastatic | 2 | nab-P 135.1. CTX 26.9 nab-P 135.1. CTX 23.1 | 1.9(1st)
3.6(2nd) |
SD | 5.0 |
| 5 | Male | 53 | iCCA | Relapsed/Metastatic | 1 | nab-P 125.0. CTX 14.3 | 1.6 | PD | |
| 6 | Male | 62 | pCCA | Unresectable | 1 | nab-P 176.5. CTX 25.0 | 2.0 | PD | |
| 7 | Male | 75 | GBCA | Unresectable | 1 | nab-P 119.1. CTX 26.7 | 1.4 | PD | |
| 8 | Female | 56 | iCCA | Metastatic | 1 | nab-P 189.9. CTX 27.6 | 2.9 | SD | 1.5 |
| 9 | Male | 61 | pCCA | Relapsed/Metastatic | 1 | nab-P 187.5.★ | 1.5 | SD | 2.0 |
| 10 | Male | 50 | PC | Metastatic | 1 | nab-P 145.6. CTX 22.2 | 2.1 | SD | 5.3 |
| 11 | Male | 74 | PC | Relapsed/Metastatic | 2 | nab-P 116.3. CTX 20.0 nab-P 115.6.☆ |
1.9(1st)
3.4(2nd) |
SD | 8.3 |
1st: the first cycle of CART-HER2 treatment; 2nd: the second cycle of CART-HER2 treatment
dCCA distal cholangiocarcinoma; iCCA intrahepatic cholangiocarcinoma; pCCA perihilar cholangiocarcinoma; GBCA gallbladder carcinoma; PC pancreatic carcinoma; nab-P nab-paclitaxel; CTX cyclophosphamide; PR partial response; SD stable disease; PD progressive disease
★CTX was canceled for a grade-3 decrease of platelet. ☆CTX was canceled for complicated upper respiratory infection